CD20, like CD19, is a specific antigen for B cells, only located in pre-B cells and mature B cells. It is expressed in more than 95% of B-cell lymphomas, but not in hematopoietic stem cells, plasma cells and other normal tissues. Therefore, it is a popular target for the treatment of lymphoma, leukemia and certain autoimmune diseases, and its application in the field of immunotherapy is very wide. The human-mouse chimeric antibody rituximab, which targets CD20, has become a classic antibody drug in tumor immunotherapy, and CAR-T , which targets CD20, has also been used in many clinical trials. This product is a second-generation CAR lentiviral expression plasmid targeting CD20 based on a human-mouse chimeric antibody (Rituximab antibody sequence) targeting CD20.

Product name: Lenti-EF1a-CD20-2nd-CAR-EGFRt

Promoter: EF1a [1]

Intracellular co-activation signal: 4- 1 BB /CD3Zata

Resistance gene: Amp

Tag: EGFRt [2]



1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.

2.  EGFRt intercepts domain III and domain IV of wild-type EGFR. This truncated EGFRt has no intracellular signal and will not transmit other signals to T cells . At the same time, these two domains are cetuximab Recognizing the epitope and expressing the epitope on T cells can not only be used as CAR-T screening markers, but also add a safety switch for clinical research. Related flow cytometry antibodies can be inquired ( iCareAb, CAT# IAB006A )